The evaluation of allogeneic adipose derived mesenchymal stem cells as a treatment for symptomatic knee osteoarthritis, specifically evaluating safety, effects on knee pain, function and structure, and quality of life in knee osteoarthritis patients.
Phase 1
Completed
- Conditions
- OsteoarthritisMusculoskeletal - Osteoarthritis
- Registration Number
- ACTRN12615000439549
- Lead Sponsor
- Regeneus Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Patients will be eligible to participate if they:
- are between 40 and 65 years of age inclusive
- have Kellgren-Lawrence grade 1, 2 or 3 symptomatic knee osteoarthritis.
- have moderate to severe knee pain associated with OA
Exclusion Criteria
Patients will not be eligible to participate if they:
- have OA in the non-study knee that has worse pain than the study knee
- have had joint surgery in the past 3 years
- have major mechanical issues in the study knee
- have significant OA in other major joints
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method